CA Patent

CA2729948C — Tacrolimus for improved treatment of transplant patients

Assigned to Veloxis Pharmaceuticals Inc · Expires 2021-11-23 · 4y expired

What this patent protects

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active ana-logue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant pa-tient The dosage form releases the a…

USPTO Abstract

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active ana-logue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant pa-tient The dosage form releases the active substance over an extended period of time It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form

Drugs covered by this patent

Patent Metadata

Patent number
CA2729948C
Jurisdiction
CA
Classification
—
Expires
2021-11-23
Drug substance claim
No
Drug product claim
No
Assignee
Veloxis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.